• p-Cresyl Sulfate Drives Aortic Valve Calcification via Kloth

  2026-07-07

  The referenced study establishes that p-cresyl sulfate, a protein-bound uremic toxin, directly enhances calcification in aortic valvular interstitial cells by downregulating klotho and sirtuin-1 signaling. These findings clarify a mechanistic link between chronic kidney disease, uremic toxins, and calcific aortic valve disease, with implications for endothelial dysfunction research and therapeutic targeting.

• PKPD Modeling of ampC/ampD Mutations in P. aeruginosa Resist

  2026-07-07

  This study elucidates how specific ampC and ampD mutations in Pseudomonas aeruginosa drive reduced susceptibility to ceftolozane-tazobactam, while partially restoring imipenem sensitivity. By employing semi-mechanistic PKPD modeling, the research quantifies both immediate and adaptive resistance effects, providing critical insights for resistance mechanism studies and antibiotic strategy development.

• Cyanidin Chloride: Advanced Workflows for Oxidative Stress M

  2026-07-06

  Cyanidin Chloride, a high-purity anthocyanin polyphenolic antioxidant from Bilberry, delivers robust, reproducible performance in oxidative stress and inflammatory skin disease models. This guide distills recent breakthroughs into actionable protocols, troubleshooting strategies, and comparative advantages for cell-based assays focused on cellular protection and barrier restoration.

• LY2603618: Chk1 Inhibitor Workflows for DNA Damage Research

  2026-07-06

  LY2603618 stands out as a highly selective Chk1 inhibitor, enabling precise control of the DNA damage response and cell cycle arrest in oncology research. This article provides actionable experimental workflows, protocol enhancements, and troubleshooting strategies, leveraging recent advances in iPSC platforms and combinatorial chemotherapy sensitization.

• AI-Driven Discovery of Senolytics: Insights for Cancer Resea

  2026-07-05

  The referenced study introduces an innovative machine learning approach that identifies novel senolytic compounds by leveraging published screening data. This strategy substantially reduces drug discovery costs and highlights new avenues for targeted elimination of senescent cells, relevant to both cancer and aging-related research.

• Anlotinib Hydrochloride: Mechanistic Advances in Multi-Targe

  2026-07-04

  Explore the in-depth pharmacology of Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor with superior anti-angiogenic and anti-proliferative activity. This article unveils new mechanistic insights and practical assay considerations for cancer research.

• Dual-Action Airway Stent Suppresses Tracheal Restenosis

  2026-07-03

  Zhao et al. introduce a novel airway stent that combines anti-inflammatory and anti-angiogenic actions to address tracheal in-stent restenosis (TISR). By integrating drug delivery and advanced material design, the stent significantly reduces fibrosis, inflammation, and vascularization, offering a promising translational solution for airway obstruction management.

• IR-820 (New Indocyanine Green): Reliable In Vivo Imaging Sol

  2026-07-03

  This article provides an evidence-based exploration of IR-820 (New Indocyanine Green, SKU C8228) in cell viability and tumor imaging workflows. Addressing real laboratory challenges, we detail how IR-820 delivers reproducible, sensitive results across in vivo near-infrared fluorescence imaging applications, with insights on protocol optimization and vendor selection.

• Saracatinib (AZD0530): Precision Src/Abl Inhibition in Cance

  2026-07-02

  Saracatinib (AZD0530) empowers cancer researchers with potent, selective Src and Abl kinase inhibition, enabling high-resolution dissection of cell proliferation, migration, and tumor growth. Its nanomolar activity, validated in diverse cancer models and translational neuroscience, makes it a cornerstone for advanced pathway interrogation and assay innovation.

• ERAD-Hijacking Chimeras Enable Targeted Degradation of TM Pr

  2026-07-02

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule technology that harnesses the ER-associated degradation pathway for efficient and selective degradation of transmembrane proteins. This innovation addresses a longstanding limitation in targeted protein degradation, expanding therapeutic and research possibilities for membrane protein modulation.

• Ferroelectric-Liquid Metal Hybrid Enables Biomimetic Visual

  2026-07-01

  A recent study introduces a ferroelectric-liquid metal hybrid film that functions as an artificial photoreceptor, closely mimicking natural human visual adaptation. This biomimetic prosthesis restores both visible and infrared light sensitivity in rodent models of retinal degeneration, showing promise for advanced retinal implants.

• LMO2-LDB1 Complex Drives AML Progression: Mechanistic Insigh

  2026-07-01

  This study uncovers the oncogenic role of the LMO2-LDB1 protein complex in acute myeloid leukemia (AML), demonstrating its necessity for leukemic cell proliferation and survival. The findings suggest that disrupting LMO2-LDB1 interactions may provide new therapeutic opportunities, with downstream implications for epigenetic and transcriptional targeting in AML.

• Dissecting Drug Responses in Cancer: Dual Metrics for Precis

  2026-06-30

  Schwartz's dissertation introduces a framework distinguishing proliferative arrest from cell death in in vitro cancer drug response assays. By clarifying the differential and overlapping effects of anti-cancer agents, the study enables more precise evaluation of therapies targeting BCR-ABL and other kinases.

• Glabridin-Gold(I) Complex Targets TrxR/MAPK for Enhanced Ant

  2026-06-30

  This study introduces a novel glabridin-gold(I) complex (6d) that synergistically targets thioredoxin reductase and MAPK pathways to remodel the immunosuppressive tumor microenvironment and enhance antitumor immune responses. The findings highlight dual pathway inhibition as a promising strategy for improving the efficacy of cancer immunotherapies.

• BMS-345541 Hydrochloride: Selective IKK Inhibitor for NF-κB

  2026-06-29

  BMS-345541 hydrochloride is a highly selective IKK inhibitor that blocks NF-κB signaling and pro-inflammatory cytokine production. Its precision and water solubility make it a standard for inflammation research and cancer biology applications.

14852 records 1/991 page Next 12345 下5页 Last page